The practical answer
FDA states that compounded drugs are not FDA approved, that semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs, and that it has warned sellers of GLP-1s labeled "for research purposes" that were sold for human use with dosing instructions. A vial sold as research semaglutide is not the approved product. [1]
Evidence, method & source dates ↓The question readers actually ask
Search results for "research semaglutide" or "research tirzepatide" mix approved medicines, compounded preparations and vials labeled for laboratory use. Readers want to know whether these are the same thing. They are not, and FDA has published specific statements explaining why. This guide records those statements as of 13 October 2026.
This is regulatory reading, not medical guidance. It contains no dosing, no comparison of effects and no advice about obtaining any product. Questions about treatment belong with a licensed clinician.
Approved products have named applications
FDA's July 2026 notice on revised draft product-specific guidances for generic peptide products lists semaglutide under the brand names Ozempic and Wegovy and tirzepatide under Mounjaro and Zepbound, among other peptide products. [5] Approval attaches to those specific products. Drugs@FDA is the place to confirm the sponsor, application and labeling for any of them. [4]
FDA states more generally that compounded drugs are not FDA approved. [3] A preparation that contains the same named ingredient but comes from another source is not covered by the approved product's application.
What FDA says about compounded and salt-form versions
On its page about unapproved GLP-1 drugs, updated 1 October 2026, FDA states that compounded drugs are not reviewed by the agency for safety, effectiveness or quality before marketing. It also states that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from those used in the approved drugs, and that FDA knows of no lawful basis for using them in compounding. [1]
The same page reports that, as of 31 May 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and cautions that such events are underreported because state-licensed pharmacies are not required to report them. [1] These are report counts, not incidence rates, and they do not establish that any individual event was caused by a product.
| Product description | FDA statement | Source |
|---|---|---|
| Approved brand product | Approved under a specific application; check Drugs@FDA | [4] [5] |
| Compounded version | Not FDA approved; not reviewed for safety, effectiveness or quality before marketing | [1] [3] |
| Semaglutide sodium or acetate | Different active ingredients from the approved drugs; no known lawful basis for compounding | [1] |
| Labeled "for research purposes" or "not for human consumption" | FDA has warned sellers that sold these for human use with dosing instructions | [1] |
Research-labeled GLP-1 sellers and the 2026 letters
FDA says it has warned companies selling unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide with research or not-for-human-consumption labels, and urges consumers not to buy them. [1] In one March 2026 letter, FDA concluded that a seller's retatrutide and tirzepatide were intended as drugs for human use despite "Research Use Only" labeling, based on weight and glucose claims on its website, and stated that no approved applications were in effect for those products. [2]
For a legitimate laboratory purchase of a GLP-1 analog as a reference material, the documentation questions are the same as for any peptide: exact identity and salt form, lot-matched analytical results, and a supplier whose marketing is consistent with research supply. Record any human-use claims you see on the supplier's site.
Write the distinction into your notes
When a document or listing names semaglutide or tirzepatide, record four fields: the exact product name, the active ingredient including salt form, the source type (approved product, compounded preparation or research-labeled material) and the supporting document. A reviewer can then see immediately whether the item is an approved product or something else.
Do not compare research-labeled material with approved products on price, potency or outcome; the documents needed to support such a comparison do not exist for the research-labeled vial.
Questions before you decide
Is research-grade semaglutide the same as Ozempic or Wegovy?
No. Approval attaches to the specific approved products. FDA warns that research-labeled versions sold for human use are unapproved, and that salt forms are different active ingredients.
Are the FDA adverse event numbers rates of harm?
No. They are counts of reports received for compounded products, and FDA notes underreporting. They do not establish incidence or causation.
Check the underlying evidence
Sources & review dates
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss ↗Accessed 13 Oct 2026
- FDA warning letter: Gram Peptides, MARCS-CMS 721806, March 31, 2026 ↗Accessed 13 Oct 2026
- FDA: Is It Really 'FDA Approved'? ↗Accessed 13 Oct 2026
- FDA: Drugs@FDA database ↗Accessed 13 Oct 2026
- FDA: Revised draft product-specific guidances for certain generic peptide products (July 2026) ↗Accessed 13 Oct 2026
Sources are documentary evidence. They do not establish firsthand testing of a listed supplier.